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Systemic hypertension versus intraglomerular hypertension in
progression
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Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany
A role for hypertension in the progression of renal failure has
been postulated for decades [1, 2], but interest in this issue has
been stimulated enormously by the recent availability of potent
and efficacious anti-hypertensive agents. In addition, the avail-
ability of suitable animal models and of techniques to assess
renal and intraglomerular hemodynamics has focused attention
on changes of intraglomerular events as non-specific factors
perpetuating damage and promoting progression [3, 41. More
recently, based on histological [5] and other observations, the
importance of extraglomerular events has also been widely
appreciated [6].
It is a difficult task to sort out the relative roles of systemic
versus glomerular hypertension in the progression of renal
disease in humans. This obviously relates to the fact that direct
measurements of glomerular capillary pressure are not possible
in humans. In the following we try to cautiously interpret such
indirect evidence as is available in this field.
Is hypertension related to progression?
The assumption that high blood pressure accelerates progres-
sion of renal failure is dignified by tradition [1, 2], but it has only
been recently that direct proof has become available. Several
retrospective studies [7—9] showed higher blood pressures in
those patients who progressed rapidly, but this approach obvi-
ously does not provide information on the cause and effect
relationship. It is possible that blood pressure happens to be
higher in individuals with intrinsically more severe and progres-
sive renal disease without being responsible for more rapid
progression. In a retrospective study [7] we were able to show
that a significant correlation existed between blood pressure at
the time of biopsy and loss of GFR over the ensuing two years
in patients with biopsy-confirmed IgA glomerulonephritis who
had been left without anti-hypertensive medication by their
private physicians. More recently prospective studies have
become available which show a significant (although surpris-
ingly weak) relation between blood pressure and loss of GFR in
early [10] and late [11, 121 renal disease. Nevertheless, only
30% of the variance for rate of loss in GFR can be explained by
blood pressure [11].
Why is this relation so difficult to demonstrate? The possibil-
ities include confounding factors. These may be non-hemody-
namic in nature. In a recent study Samuelson et al [131 showed
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that hemodynamic factors, that is, systolic blood pressure, and
metabolic factors, such as apolipoprotein B concentrations,
interact with the highest risk being conferred by the combina-
tion of high blood pressure and high apolipoprotein B concen-
trations. There may also be hemodynamic confounders. Renal
disease causes an abnormal circadian blood pressure proffle. In
diabetics, Benhamou et al [14] noted that night time blood
pressure was significantly higher in diabetic patients with mi-
croalbuminuria than in patients without. The abnormality in
circadian blood pressure may also be relevant in non-diabetic
renal disease. In a prospective study, Del Rosso [15] found that
the rate of decrease in C, was greater in patients without a
nocturnal blood pressure fall. Even more important may be
intermittent bursts of elevated blood pressure. Helmchen,
Kneissler and Bohle [16] examined vascular lesions in preglo-
merular vessels immediately after a Goldblatt clip. Short-lasting
intermittent bursts of elevated blood pressure were related to
the occurrence of vascular lesions, although baseline blood
pressure was still completely normal. This also may be relevant
in the remnant kidney model, since intermittent bursts of
elevated blood pressure were more correlated to the develop-
ment of glomerulosclerosis than baseline blood pressure [171.
Gender is known to affect progression; not only is renal
prognosis worse in males [18], but the relation between blood
pressure and progression is also much tighter in males as
compared to females [11]. Another problem is whether systolic,
mean arterial or diastolic blood pressure are most closely
related to progression. Systolic blood pessure has been found to
be the most potent predictor of cardiovascular accidents in
patients with primary hypertension; this may reflect the relation
between peak systolic pressure and peak wall stress in large
conduit arteries. In the renal microcirculation blood flow is not
discontinuous, however. This may explain observations that
diastolic blood pressure correlates better with progression than
does systolic blood pressure [11, 191.
Is the effect of hypertension on progression mediated
exclusively via acceleration of glomeruloscierosis?
Today the concept has been widely accepted that the adverse
effect of blood pressure on renal function is mediated via
glomerulosclerosis [4]. This notion is certainly correct, but may
not be the full answer. In 1923 Volhard [1] thought that
hypertension caused vascular sclerosis which in turn provoked
ischemia and thus accelerated progression. Subsequently, this
view has been largely abandoned. It is worth pointing out,
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Fig. 1. Meta-analysis of 77 studies describing
the effects of ACE inhibitors, conventional
antihypertensive agents and Ca antagonists
on albuminuria or proteinuria (29]. The graph
shows the percentage change in albuminuria
or total proteinuria as related to blood
pressure changes in diabetic patients on
different antihypertensive drug treatments.
Note that at no change in mean blood
pressure, ACE inhibitors cause an
approximately 20 to 30% decrease in 24-hour
urine albumin or total protein. As blood
pressure is progressively lowered, the
difference between ACE inhibitors and
conventional antihypertensive agents
diminishes (with permission from Nephrol
Dial Transplant).
Fig. 2. Effect of enalapril on glomerular
architecture after subtotal nephrectomy. Ten
animals each were subtotally nephrectomized
(NX) or sham operated. Matched pairs of
animals were pair fed. The graph shows
glomerular volume (as an index of glomerular
growth), mesangial cell nuclei per glomerulus
(as an index of glomerular cell proliferation)
and mesangial cell nuclear volume (as an
index of mesangial cell activation) 8 weeks
after subtotal nephrectomy by stereological
analysis. All differences between NX versus
sham operated groups and untreated versus
enalapril-treated groups were significant (P <
0.001 for glomerular volume and mesangial
cell nuclei and 0.05 for mesangial cell nuclear
volume; N = 8 animals per group, data as
X SD).
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Table 1. Stimulatory effect of Ang II on DNA synthesis (3H-
thyinidine incorporation) or human adult mesangial cells
24hr 36hr 48hr
Control 2141 362 1627.5 663.9 1684.7 132
Angiotensin 1110—6 M 2661.3 209k 2191.9 113 2411 I25
Angiotensin II l0 M 2739,2 578k 1962 156 2011.2 405
Angiotensin II 10'° M 2530.2 186 1909.3 349 1918.9 292
Angiotensin 1110—8 54 2332.6 234 1175.2 232 1558.3 143
DUP 753 i0 M
Data are x sn (cpm/8 hr of incubation).
a P < 0.05 vs. controls (Wilcoxon test) studying of dishes with 3000
cells/dish, 10 parallel dishes, growth 48 hours in 20% FCS/RPMI,
subsequently for synchronization 48 hours serum-free medium (MCDB-
302), then addition of agonist or solvent (control) and postincubation for
period indicated under serum-free conditions, addition of 3H-thymidine
(1 Ci/ml) 8 hours prior to harvesting serum-free medium was changed
every 24 hours.
however, that renal failure may occur in the presence of
so-called "benign" nephrosclerosis [20]. "Benign" nephroscle-
rosis is occasionally associated even with nephrotic range
proteinuria [21, 221. A large proportion of elderly patients
reaching end-stage renal failure suffers from ischemic nephrop-
athy, up to 15% of patients over 55 years of age [23]. Zucchelli
and Zuccala [241 examined 150 patients with ischemic nephrop-
athy by renal angiography and biopsy. No less than 30% of
these patients had "benign" nephrosclerosis. It is therefore
conceivable that both vascular lesions (causing ischemia) and
glomerular strain (causing segmental glomeruloscierosis) coex-
ist. Coexistance of ischemic and overperfused nephrons has
also been postulated in primary hypertension, and this may
have important repercussions on the relation of the activity of
the renin-angiotensin system. It should also be pointed out that
the mechanism of progression may vary according to disease.
Zeier et a! [25], for instance, documented that segmental
glomerulosclersis, the putative marker of glomerular hyperten-
sion, was virtually absent in patients with polycystic kidneys
who had gone into renal failure while vascular sclerosis and
interstitial fibrosis were prominent.
Is glomerular hypertension more important for progression
than systemic hypertension?
Since glomerular capillary pressure cannot be measured
directly, all conclusions in this regard must remain speculative.
Indirect conclusions, at least concerning the direction of change
in capillary pressure have been drawn from two pieces of
information. These are: (i) the sieving properties for neutral
dextrans [26, 27], and (ii) the differential effects of anti-hyper-
tensive agents on proteinuria (as a surrogate marker of glomer-
ular injury) and progression of renal failure (as a hard end
point).
All these parameters are dubious to some extent. For in-
stance one may question whether albuminuria is an adequate
marker of glomerular injury. At least in animal studies, most of
the albumin was shown to originate in glomeruli without lesions
[28]. A differential effect of anti-hypertensive agents on progres-
sion may also not reflect different actions on glomerular capil-
lary pressure (as originally postulated because of the preferen-
tial action of ACE inhibitors on efferent resistance) but may, at
least in part, be due to non-hemodynamic actions.
Certainly ACE inhibitors are superior to alternative anti-
hypertensive agents with respect to their anti-albuminuric ef-
fects [29]. As shown in Figure 1, a recent meta-analysis
documents that the anti-albuminuric effects of ACE inhibitors
can be dissociated from blood pressure lowering. Interestingly,
the slope describing reduction of albuminuria as a function of
the decrement in blood pressure differs between ACE and
alternative anti-hypertensive agents. With progressive lowering
of blood pressure, the anti-albuminuric action of ACE inhibitors
increases less. It is obvious from Figure 1 that a difference or no
difference between ACE inhibitors and alternative anti-hyper-
tensive agents is noted, depending on how markedly blood
pressure has been lowered. This may explain some of the
controversies in the literature. Not only can the effect of ACE
inhibitors on albuminuria be dissociated from their action on
systemic blood pressure, but several observations also argue
against a purely hemodynamic mechanism of action. The anti-
albuminuric effect is progressive with time although blood
pressure remains at a constantly low level [30]; furthermore,
albuminuria does not rise acutely when blood pressure has been
chronically lowered by ACE inhibitors and is acutely raised by
infusion of angiotensin II (Ang II) [311. Whether such delayed
actions of ACE inhibitors on proteinuria are mediated by
glomerular remodeling or by long-term actions related to the
accumulation of kinins remains unclear. Nevertheless, with
respect to the latter possibility, the observation of Hutchison
and Webster [32] is of interest that the anti-proteinuric effect of
enalapril is not completely duplicated by the administration of a
specific Ang II receptor antagonist in a rat model of nephrotic
proteinuria.
Recent randomized, controlled prospective trials seem to
confirm animal studies [33] that with respect to preserving renal
function ACE inhibitors are superior to equi-hypotensive doses
of betablockers in patients with diabetic nephropathy [34] or
other types of renal disease [35, 36]. Nevertheless, the conclu-
sion that ACE inhibitors are superior because of, or only
because of, selective lowering of glomerular capillary pressure,
may be premature. It is evident that ACE inhibitors affect
charge selectivity and size selectivity of the glomerular capil-
lary barrier in humans [37, 38]; at least in animals, ACE
inhibitors also affect glomerular structure. Amann et al [39]
recently showed that after standardized renal ablation, glomer-
ular volume and glomerular cell numbers were significantly less
in enalapril treated animals compared to untreated, subtotally
nephrectomized controls (Fig. 2). Sequential biopsy studies in
patients on CEI are needed to exclude this possibility in
humans.
Recent studies in our laboratory provide further information
in this respect [40]. In mesangial cells grown from adult
humans, Ang II dose-dependently and specifically increased
radiothymidine incorporation (as an index of DNA synthesis;
Table 1) and cell proliferation (growth curve) (Fig. 3). In
parallel, cell protein content was increased (Fig. 4), an effect
that has previously also been shown in vascular smooth muscle
cells. Although the magnitude of the effect is not impressive and
although the in vivo relevance of this in vitro phenomenon
remains uncertain, the findings illustrate the need to consider
changes in glomerular architecture by CEI as an alternative (or
complementary) mode of action.
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Fig. 4. Effect ofAng II in the absence and presence of saralasin on the
total protein content of human adult mesangial cells. Symbols are: (U)
control; () Ang II l0_8 M; (EJ) saralasin l0 M, () Ang II +
saralasian. Adult hMC were plated in culture dishes and grown with
RPMI 20% FCS. Forty-eight hours prior to the experiment the medium
was changed to serum free medium to render cells quiescent. At time 0
medium was changed and cells were grown in serum-free medium with
addition of the agonists as indicated in the figure. Total protein content
in the cell lysate was measured with BCA protein assay reagent. The
results were confirmed in 6 independent experiments.
Does Ang II play a role in progression?
Many investigators have been puzzled by the paradox that
CEI are effective in renal failure although PRA is low. Although
it is low, PRA may be inappropriate, however. PRA does not
adequately respond to stimulatory and suppressive maneuvers
[411 and is abnormal in relation to exchangeable sodium and
blood pressure [42]. Both in diabetes and in the remnant kidney
model after ligation of renal arteries but not, however, after
partial surgical resection (unpublished observations), renin, by
immunostaining, and renin mRNA message are clearly in-
creased in rats [43, 44]. Using PCR with a mutant template
technique for quantitation we have recently been able to detect
renin mRNA in patients with primary chronic glomerulonephri-
tis; the amount was lower than in controls [45]. Nevertheless,
such low levels may still be inappropriate and do not exclude a
role of Ang II in progression, particularly as complete assess-
ment of the full impact of the renin system on progression
Fig. 3. Effects of Ang II in the absence (A)
and presence (B) of PDGF on the growth
curve of adult human mesangial cells (hMC).
Symbols are: (—) PDGF alone (ng/ml); (- - -)
PDGF + Ang 11(10-6 M); in A: (0) Ang II
10 M; (U) Ang 1110-8 M, (•) Ang II 100
M; (A) control; (U) Ang III 10—6 in B: (x)
B PDGF 50 + Ang II; (•) PDGF 50; (A) PDGF10; (0) PDGF 10 + Mg II; (0) PDGF 1 +
Ang 11; (A) PDGF 1; (U) control. A total of
25,000 hMC/well were seeded 48 hours prior
to addition of the agonists into 24-well Falcon
culture plates and grown with RPMI 20% FCS
(or 10% PDS; plasma derived serum; data not
shown, differences between groups similar).
At time 0 medium was changed and cells were
grown in serum-free medium with addition of
the agonists as indicated in the figure.
Medium was changed every 24 hours. Each
point is the average of triplicate counts of 8
wells per data point. Significant difference of
AO Ang II 106 M versus control after 48 hours and0 PDGF 10 and 50 ng/ml versus control after 24
hours (P < 0.01). No significant difference of
Time, hours PDGF without versus PDGF with Ang II.
would require quantitation of all components including ACE
activity, Ang II receptor activity, postreceptor events and
activity of counter regulatory systems. The more rapid deteri-
oration of renal function in the transgenic REN 2 model with
overexpression of renin, compared to SHR with similar blood
pressure, would also be consistent with a specific non-hemody-
namic role of Ang II in progression [46].
It follows from the above that currently no firm statements
with respect to the relative role of systemic versus glomerular
hypertension can be made, at least in humans. Nevertheless, a
number of rational working hypotheses can be formulated
which in the future will be susceptible to experimental verifi-
cation.
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